20:16:16 Europe / Stockholm

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget är verksamma inom den skandinaviska marknaden. Newbury Pharmaceuticals har sitt huvudkontor i Lund.

Kalender

2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2
2021-08-19 08:00:00

Lars Minor assumes the new role from September 1, 2021 and will be stationed at Newbury´s office at Medicon Village in Lund. He will be responsible for the company´s overall strategy and provide the necessary direction, business development and commercial operation. Karl Karlsson will continue fulltime as Newbury´s Executive Chairman.

We are delighted to onboard Lars as the new CEO while we target significant growth the coming years and establish ourselves as a local champion for specialty prescription drugs in Scandinavia. Lars’ strong background in commercial leadership roles makes him well suited to, together with the leadership team, build Newbury into a successful company” says Karl Karlsson, Founder & Executive Chairman.

Lars’ previous position was Corporate Vice President for strategy and execution at LEO Pharma, responsible for leading the global strategy. Prior to that position Lars has had P&L responsibility for emerging markets and Europe at LEO Pharma. He has notable experience in negotiations, business development and alliance management combined with extensive experience from scaling businesses for growth and regional market experience in Europe. Lars combines strong pharmaceutical and operational expertise with strategic and commercial thinking.

“Newbury Pharmaceuticals’ hybrid business model with a combination of innovative products, orphan drugs and niche generics, as well as branded and value-added formulations, is very exciting. I look forward to grow the business and evolve the portfolio the next coming years” says Lars Minor.